. Author manuscript; available in PMC: 2024 May 13.

Published in final edited form as: Gynecol Oncol. 2023 May 25;174:253–261. doi: 10.1016/j.ygyno.2023.05.011

Table 1.

Odds Ratios for HPV genotyping and cytology tests combinations.

		Cytology Result^*
	HPV Genotype^*	NILM	ASC-US/LSIL	ASC-H/HSIL	AGC
OR for AC/AIS (95%CI)	HPV Other HR+	1	0.75 (0.18–3.2)	4.6 (0.88–24)	0 (0–0)
OR for AC/AIS (95%CI)	HPV 16/18/45+	69 (22–220)	22 (8.3–56)	152 (60–389)	1341 (495–3630)
OR for SCC/CIN3 (95%CI)	HPV Other HR+	1	1.6 (1.2–2.0)	11 (8.6–14)	2.1 (1.1–4.1)
OR for SCC/CIN3 (95%CI)	HPV 16/18/45+	3.1 (2.1–4.7)	4.6 (3.5–6.2)	32 (23–44)	38 (10–142)

NILM: negative for intraepithelial lesion or malignancy; ASC-US: atypical squamous cells of undetermined significance; LSIL: low-grade squamous intraepithelial lesion; ASC—H: atypical squamous cells cannot exclude high-grade squamous intraepithelial lesion; HSIL: high-grade squamous intraepithelial lesion; AGC: atypical glandular cells; AC: adenocarcinoma; AIS: adenocarcinoma in situ; SCC: squamous cell cancer; CIN3: cervical intraepithelial carcinoma grade 3.

All these test results are obtained at the enrolment of each individual in PaP cohort.